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Abstract
Class III drugs prolong the QT interval by blocking mainly the delayed rectifier rapid potas-
sium outward current (IKr), with little effect on depolarization. This K+ channel in encoded by
the human ether-a-go-go-related gene (hERG). Inhibition of hERG potassium currents by class
III antiarrhythmic drugs causes lengthening of cardiac action potential, which produces
a beneficial antiarrhythmic effect. Excessive prolongation of the action potential may lead to
acquired long QT syndrome, which is associated with a risk of “torsade de pointes”. Class III
agents can block all types of potassium channels: IKs, IKr, IKur and IK1. The main represent-
ing class III agent is amiodarone. It is the gold standard in the prevention of recurrence of
atrial fibrillation. Although it is highly effective in treating many arrhythmias, large number of
adverse effects limits its clinical use. Dronedarone is a synthetic amiodarone analogue, iodine-
free compound, with fewer adverse effects, and shares amiodarone’s multichannel blocking
effects, inhibiting transmembrane Na+, IKs, IKur, IK1, and slow Ca++L-type calcium cur-
rents. The main new generation class III drugs are: dofetilide, dronedarone, azimilide, and
ibutilide. Oral dofetilide did not increase mortality in patients with a recent myocardial
infarction or congestive heart failure. It is an alternative for the pharmacological conversion of
atrial fibrillation and flutter. Azimilide blocks both rapid and slow potassium channels compo-
nents. Azimilide is not a methanesulfonanilide compound. Trecitilide, tedisamil, ersentilide,
ambasilide, chromanol and sematilide are class III miscellaneous agents. Old mixed agents
are sotalol and bretylium. The present article reviews the main trials accomplished with these
drugs. (Cardiol J. 2008; 14: 209–219)
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Introduction
The list of drugs involved in the QT/QTc pro-
longation is continuously increasing. It is principally
linked to a block of the outward potassium current
IKr, with as a consequence a prolongation of the
repolarization causing early after potentials and
reentry. Some drugs prolong QTc in a dose-depen-
dent manner; others do so at any dose [1].
The term “repolarization reserve” expresses
the variable risk of arrhythmia among individuals
under the same drug blocking IKr. The human
ether-a-go-go-related gene (hERG) potassium
channel has elicited intense scientific interest due
to its counter-intuitive kinetics and its association
with arrhythmia and sudden death (SD). hERG bloc-
kade is involved in both antiarrhythmic pharmaco-
therapy and the pathogenesis of familial and acqu-
ired long QT syndrome (aLQTS). This reserve can
be altered under various pathologic or genetic con-
ditions. Pathophysiologically significant ion-channel
mutations have been detected in only a minority of
cases of aLQTS. Previously unsuspected LQTS
mutations may be present in patients with antiarr-
hythmic drug-associated torsade de pointes (TdP).
A normal QTc interval does not exclude the risk of pro-
arrhythmia [2]. Congenital long QT syndromes cause
perturbation of ventricular repolarization causing QT
prolongation on surface electrocardiogram (ECG).
The aLQTS are caused mainly by drugs.
On the other hand, approximately 7.5% of cau-
casians are genetically lacking Cytochrome P450
CYP2D9 from their enzymatic system, which is
necessary for the metabolization of drugs with the
potential to cause QT interval prolongation. When
they are administered and not properly metaboli-
zed, and concomitant with the genetic mutation of
LQTS, the risk of events of TdP increases, since
the half life of these drugs is extended. Risk pre-
diction is difficult particularly for non cardiovascu-
lar drugs and a low risk incidence. Another risk is
to exclude patients from the benefit of an efficient
drug for a serious but not frequent risk, and at last,
there is an industrial risk for the manufacturer
when a drug is withdrawn late when important qu-
antities of money have already been invested for
its development.
Other causes of aLQTS are electrolytic disor-
ders, cardiac disease (myocardial infarction, dilated
cardiomyopathy, mitral valve prolapse, neurologi-
cal diseases, dietary deficiencies, severe malnutri-
tion among anorexic patients, chronic arsenic expo-
sure [3], cesium chloride supplement [4], female
gender etc.
The diagnosis of TdP is easy on standard ECG
although QT measurement and its heart rate varia-
tion remain uneasy. The treatment of TdP imme-
diate defibrillation for hemodynamic instability is
based on heart rate acceleration by isoprenaline or
cardiac pacing, potassium (if hypokalemic) and in-
travenous magnesium sulfate [5]. Other alternati-
ve or non drug therapy is removing causative
agents.
Moderate hERG blockade may produce a be-
neficial class III antiarrhythmic effect. In contrast,
a reduction in hERG currents due to either genetic
defects or adverse drug effects can lead to heredi-
tary or aLQTS characterized by action potential
(AP) prolongation, lengthening of the QT interval
on the surface ECG, and an increased risk for “tor-
sade de pointes” arrhythmias and sudden death.
Drug-induced LQTS is characterized by a prolonged
corrected QT interval (QTc) and increased risk of
a polymorphic ventricular tachycardia (VT). Class III
drugs prolong repolarization (increase refractori-
ness) by blocking outward potassium conductance
(prolong QT interval), with typically little effect on
the rate of depolarization (no effect on QRS interval).
All drugs that prolong QTc block the rapid com-
ponent of the delayed rectifier current (IKr). Some
drugs prolong QTc in a dose-dependent manner;
others do so at any dose [1]. The increasing under-
standing of hERG channel function and molecular
mechanisms of hERG current regulation could im-
prove prevention and treatment of hERG-associa-
ted cardiac repolarization disorders.
Most patients that develop drug-induced TdP
have underlying risk factors. Female sex is the most
common. Implicated drugs include class 1A and III
antiarrhythmics, macrolide antibiotics, pentamidi-
ne, antimalarials, antipsychotics, arsenic trioxide,
and methadone. These drugs should be used with
caution in female patients prone to bradycardia.
Potassium channel blockade
Potassium channels, particularly the channel
giving rise to the “delayed rectifier current”, are
activated during the repolarization (Phase 3) of the
action potential. Blockade of potassium channels
prolongs AP duration (APd).
Prolongation of APd usually results in an incre-
ase in effective refractory period. Many of the drugs
that prolong repolarization (class III drugs, potas-
sium channel blockers) exhibit negative or reverse
rate dependence.
These drugs have little effect on prolonging
repolarization in rapidly depolarizing tissue. These
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drugs can cause prolongation of repolarization in
slowly depolarizing tissue or following a long com-
pensatory pause, leading to repolarization distur-
bances and torsade de pointes.
Repolarization of cardiomyocytes is mainly
performed by the rapid component of the delayed
rectifier potassium current, IKr, which is encoded
by hERG. Inhibition of hERG potassium currents
by class III antiarrhythmic (Table 1) drugs causes
lengthening of the cardiac AP, which produces
a beneficial antiarrhythmic effect. Conversely,
excessive prolongation of the AP by a wide variety
of antiarrhythmic and non-antiarrhythmic drugs
may lead to aLQTS, which is associated with a risk
for TdP arrhythmias and SD [6].
I. Main representative agent
Amiodarone
Although amiodarone is approved by the US
Food and Drug Administration (FDA) only for re-
fractory ventricular arrhythmias, it is one of the
most frequently prescribed antiarrhythmic medica-
tions in the United States. The drug is the gold stan-
dard in the prevention of recurrence of atrial fibrilla-
tion (AF). Amiodarone is among the most effective
with the additional advantage of having little proarr-
hythmic potential. The favorable efficacy profile of
amiodarone during electrical remodeling, particu-
larly the marked increase in amiodarone on atrial
refractory periods prolongation in early electrical
remodeling, may explain its superior clinical effi-
cacy over existing antiarrhythmic drugs [7]. Amio-
darone has a low incidence of cardiac adverse
events, including TdP. In elderly women long-term
amiodarone treatment could result of combined
block of the rapid (IKr) and slow (IKs) delayed
outward potassium current (IK) components, trans-
lated to the ECG in a (more than expected) prolon-
ged QT interval, an augmented transmural disper-
sion of repolarization (TDR) and an interrupted
T wave. The unequal regression of repolarization
lengthening made possible to individualize IK cur-
rent components in the inscription of the interrup-
ted T wave, which argues against the U wave as
a separate entity. Silent ion channel gene mutations
or polymorphisms and downregulation of beta-ad-
renergic activation of IKs may underlie the unusu-
al repolarization behavior. The unequal regression
over time of amiodarone induced repolarization
lengthening could have clinical significance [8].
Amiodarone should be used with close follow-up in
patients who are likely to derive the most benefit,
namely those with AF and left ventricular (LV) dys-
function, those with acute sustained VT, those abo-
ut to undergo cardiac surgery, and those with im-
plantable cardioverter-defibrillators and symptoma-
tic shocks [9]. Although this drug is highly effective
in treating many arrhythmias, its numerous adver-
se effects limit [10–13] its clinical use. Adverse ef-
fects are common (more than 75% of patients re-
ceiving the drug) and increase after a year of treat-
ment; some toxicities result in death. Half-life of
25–110 days can prolong toxicity.
II. New generation agents
Dofetilide
Structure. Dofetilide is a novel, highly speci-
fic class III methanesulfonanilide anti-arrhythmic
drug.
Action mechanism. Dofetilide is a relatively
new class III antiarrhythmic agent that selectively
blocks the rapid component of the cardiac ion chan-
nel delayed rectifier current. Dofetilide works by
selectively blocking the rapid component of the
delayed rectifier outward potassium current (IKr).
The drug appears to primarily block activated chan-
nels and has a much lower affinity for closed and
inactivated channels [14]. At nanomolar concentra-
tions this agent prolongs both the atrial and ventri-
cular effective refractory periods and AP duration.
Dofetilide does not appear to interact with other
cardiac ion channels, and this explains its minimal
effects upon conduction velocity, myocardial
Table 1. Class III antiarrhytmics.
I. Main representative agent
Amiodarone
II. New generation’s agents
Dofetilide
Dronedarone
Azimilide
Ibutilide
III. Miscellaneous agents
Trecitilide
Tedisamil
Ersentilide
Ambasilide
Chromanol 293B
Sematilide
IV. Others old agents
Sotalol (combined class II/III)
Bretylium
Observation: In this manuscript we do not undertake group IV.
212
Cardiology Journal 2008, Vol. 15, No. 3
www.cardiologyjournal.org
contractility and systemic hemodynamics. Unlike
other antiarrhythmic agents, oral dofetilide did not
increase mortality in patients with a recent myocar-
dial infarction (MI) or congestive heart failure (HF),
hence its importance as an alternative medication
for the pharmacological conversion of AF and flut-
ter, and maintenance of sinus rhythm (SR) after co-
nversion in patients at high risk of SD [15].
Dofetilide prolongs the QT interval with little
effect on QT dispersion. No effect on conduction
parameters PA, AH, M HV, PR or QRS intervals,
sinus cycle length or sinus node recovery.
Elimination. Renal and hepatic (CYP3A4 fami-
ly). In patients with kidney disease higher blood le-
vels may occur, which may increase the chance of side
effects. Safety in severe liver disease is unknown.
Doses. For oral dosage form (capsules): adults
— 125–500 mg two times a day.
Clinical use. Termination of supraventricular
arrhythmia (prevention of recurrent AF or atrial
flutter) and VT [increasing the electrical threshold
for inducible VT/ventricular fibrillation (VF)]. Do-
fetilide is approved by the FDA for conversion to
and maintenance of SR in patients with persistent
AF. Dofetilide is not indicated in patients with pa-
roxysmal AF.
Main trials with dofetilide
EMERALD trial. The European and Austra-
lian Multicenter Evaluative Research on AF Dofe-
tilide was a dose-finding study with the primary goal
of assessing the safety and efficacy of oral dofetili-
de and sotalol in preventing recurrence of AF.
Three cases of TdP occurred, all in women rece-
iving dofetilide 500 µg twice/day. This study sug-
gests dofetilide is an effective new therapeutic
option for AF. However, the relatively low dosage
of sotalol and the fact that this study is published
only in abstract form and precludes confirmation of
only previously cardioverted patients included in
the maintenance analysis creates questions regar-
ding the validity of this trial. Oral magnesium l-lac-
tate raises intracellular magnesium concentrations
and lowers the QTc interval of patients receiving
sotalol or dofetilide [16].
SAFIRE-D trial. In the Symptomatic Atrial
Fibrillation Investigation Research on Dofetilide
oral dofetilide was evaluated for its ability to convert
and maintain SR in patients with chronic AF (85%
of patients) or atrial flutter.
After the first 105 patients were enrolled, the
dosing protocol was altered to adjust for baseline
renal function (creatinine clearance) and change in
QTc interval duration. There were two cases of
nonfatal TdP considered a result of dofetilide the-
rapy; both occurred within the first 3 days of thera-
py. Prolongation of QTc duration accounted for
10 withdrawals, and one SD occurred. Dosage ad-
justment based on creatinine clearance or QTc pro-
longation was required in 33% of patients.
The SAFIRE-d trial found dofetilide to be
significantly more effective in maintaining SR at
1 year, when compared with placebo. However, the
absolute efficacy rates were moderate and probably
the result of a high frequency of heart failure in the
patient population. Finally, as a result of this trial,
starting therapy in the hospital and adjusting dosage
based on creatinine clearance and QTc prolongation
are required to minimize the risk of proarrhythmia.
DIAMOND trial. In the Danish Investigations
of Arrhythmias and Mortality on Dofetilide study
[17] dofetilide does not affect mortality in the tre-
atment of patients’ post-MI with LV dysfunction.
Because of the results of the DIAMOND study,
many physicians use dofetilide in the suppression
of AF in individuals with LV dysfunction.
Side effects. Due to its very specific mode of
action, dofetilide has very few systemic side-effects.
Dofetilide represents a novel and promising new
class III agent [18].
Like other drugs that affect potassium cur-
rents, the prolonged QT interval occurring in the
patients treated with dofetilide can be complicated
by TdP. It is the most serious side effect. The inci-
dence of TdP is dose-related, and is 0.3–10.5%. The
risk appears to be dose-dependent, with an incre-
ased incidence of TdP associated with higher do-
ses of dofetilide administered. The risk of inducing
TdP can be decreased by taking precautions when
initiating therapy, such as hospitalizing individuals
for a minimum of three days for serial creatinine
measurement, continuous telemetry monitoring
and availability of cardiac resuscitation. Severity of
HF, female gender, and QTc duration make it po-
ssible to identify patients with a high risk of early
TdP when treated with dofetilide. Patients with
recent MI less often had TdP compared with pa-
tients with chronic HF [19].
In patients with paroxysmal AF and normal LV
function, treatment with dofetilide was successful
in less than 20% of patients. Despite careful pre-
cautions, serious proarrhythmias, the major limiting
side effect of dofetilide, still occurred during long-
term follow-up [20]. It is generally well tolerated
but like other antiarrhythmic agents in its class, TdP
may be induced as a consequence of therapy. This
risk is minimized by dosage adjustment according
to creatinine clearance and QT(c) interval, by
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selecting patients without known risk factors for
TdP and by initiating treatment in a monitored ho-
spital setting for the first 3 days.
Pregnancy. Dofetilide has not been studied in
pregnant women. However, studies in animals have
shown that dofetilide causes fetal defects.
Breast-feeding. It is not known whether do-
fetilide passes into breast milk. However, the ma-
nufacturer does not recommend breast-feeding
while taking dofetilide.
Interaction with other drugs:
— antiarrhythmic or other cardiac medicine, such
as amiodarone taken within the last 3 months or;
— antibiotics like macrolides or trimethoprim, alo-
ne or in combination with sulfamethoxazole
(CYP3A4 family);
— bepridil;
— cimetidine;
— cisapride;
— megestrol;
— phenothiazines like prochlorperazine or triflu-
operazine;
— tricyclic antidepressants like amitriptyline or
desipramine;
— verapamil may cause irregular heartbeats;
— hydrochlorothiazide/triamterene may increase
serum levels of dofetilide.
Dronedarone
Dronedarone is an investigational antiarrhyth-
mic benzofuran derivative agent that is designed to
have similar cardiac effects to amiodarone but with
fewer adverse effects [21]. Dronedarone is a potas-
sium channel antagonist, chemically related to
amiodarone. It is a new synthetic noniodinated de-
rivative of amiodarone [22]. It is being developed
by sanofi-aventis as a class III antiarrhythmic agent
for the treatment of AF and atrial flutter in the US
and Europe. The drug has multiple electrophysio-
logic actions, similar to amiodarone, but without the
iodine moiety seen with amiodarone. Dronedarone
shares amiodarone’s multichannel blocking effects,
inhibiting transmembrane Na+, K+, Ca2+, and slow
L-type calcium channels, as well as its antiadrener-
gic effects. Unlike amiodarone, it has little effect on
thyroid receptors [23].
Dronedarone is an amiodarone analogue recen-
tly developed iodine-free compound (Sanofi Recher-
che), structurally related to amiodarone. Some early
data, at least from animal work, suggests that dro-
nedarone is less thyro-toxic and perhaps less pul-
monary toxic [24].
Dronedarone has a shorter half-life and can be
loaded more easily than amiodarone. If indeed
dronedarone were less toxic, the fact that it can be
administered more rapidly would give it a distinct
advantage. Clinical trials have to be completed to
determine if these are true properties of the drug.
Dronedarone reduces renal creatinine and
N-methylnicotinamide (NMN) clearance by about
18%, without evidence of an effect on glomerular
filtration rate, renal plasma flow or electrolyte
exchanges. This suggests a specific partial inhibi-
tion of tubular organic cation transporters. A limi-
ted increase in serum creatinine is therefore expec-
ted with dronedarone treatment, but does not mean
there is a decline in renal function [25].
Antiarrhythmic pharmaceutical development
for the treatment of AF is moving in several direc-
tions. Efforts are being made to modify existing
agents, such as amiodarone, in an attempt to ame-
liorate safety and adverse effect concerns [26]. Dro-
nedarone induces a marked reduction in sinus node
automaticity, evidenced by decrease in spontane-
ous heart rate, AP amplitude, and slope of phase
4 depolarization.
Isoproterenol dose-dependently increases
sinus node automaticity in the presence of either
amiodarone or dronedarone. Dronedarone resem-
bled amiodarone in class III and sympatholytic ef-
fects, indicating its potential as a unique antiarrhy-
thmic compound seemingly devoid of the side
effects mediated by iodine in amiodarone.
Dronedarone prolongs RR and QT intervals as
a function of dose, without effect on circadian pat-
terns. The relative prolongations of QT, QTc, and
RR by dronedarone are significant. The QTc inte-
rval does not exhibit a clearly recognizable circa-
dian pattern, suggesting that the circadian pattern
of the QT interval is mostly a reflection of circa-
dian changes in the RR interval [27]. Dronedarone
may be a useful antiarrhythmic alternative to amio-
darone in the treatment of supraventricular arrhy-
thmias [28]. It is a new antiarrhythmic treatment
of AF [26]. Further studies are needed to better
define dronedarone’s safety profile and place in the-
rapy [29]. In two identical multicenter, double-blind,
randomized trials, dronedarone (400 mg of the drug
twice daily) was significantly more effective than
placebo in maintaining SR and in reducing the ven-
tricular rate during recurrence of AF or flutter. Ad-
ditionally, rates of pulmonary toxic effects and of
thyroid and liver dysfunction were not significantly
increased in the dronedarone group [30].
The DAFNE trial (Dronedarone Atrial Fibril-
lation Study after Electrical Cardioversion) [31].
This study was designed to determine the most ap-
propriate dose of dronedarone for prevention of AF
214
Cardiology Journal 2008, Vol. 15, No. 3
www.cardiologyjournal.org
after cardioversion. It was the first prospective ran-
domized trial to evaluate its efficacy and safety. The
study concludes that dronedarone, at 800 mg daily
dose, appears to be effective and safe for the pre-
vention of AF relapses after cardioversion. The
absence of thyroid side effects and of proarrhyth-
mia are important features of the drug.
The ATHENA trial (A Trial with Dronedaro-
ne to Prevent Hospitalization or Death in Patients
with Atrial Fibrillation) is an interventional, preven-
tion, randomized, double-blind, placebo controled,
parallel assignment, efficacy multinational study,
evaluating the effects of dronedarone (400 mg b.i.d.)
compared with placebo, over a minimum 12-month
follow-up period, in patients with AF or flutter.
The trial is investigating the efficacy of droneda-
rone in preventing cardiovascular hospitalizations
or death from any cause. The primary efficacy pa-
rameter is the combined endpoint of cardiovascu-
lar hospitalization and death. Secondary efficacy
parameters are death of any cause, cardiovascu-
lar death, cardiovascular and non-cardiovascular
hospitalization.
Previously, Sanofi-Aventis completed two pi-
votal phase III trials in AF. The trials, EURIDIS
Dronedarone for the Maintenance of Sinus Rhythm
(EURopean trial In AF or flutter patients for the
maintenance of SR), American-Australian-African
Trial with Dronedarone in Atrial Fibrillation/Flut-
ter Patients for the Maintenance of SR (ADONIS),
dronedarone 400 mg b.i.d. showed significant effi-
cacy against placebo in prevention of AF recurren-
ce. The study involved 1237 patients who were in
SR at the time of randomization. Results showed
dronedarone to have anti-arrhythmic effects and
a favorable benefit/risk ratio, with the absence of
any proarrhythmic effect.
ERATO (Efficacy and safety of dronedARone
for The Control of ventricular rate), took place in
35 centres across nine European countries asses-
sing dronedarone in 174 patients with permanent
AF. Dronedarone was in phase II trials in Japan for
the treatment of AF; however, no recent develop-
ments have been reported.
ANDROMEDA trial raises safety concerns for
patients with congestive heart failure and moderate to
severe LV dysfunction. Dronedarone appears to be ef-
fective in preventing relapses of AF and atrial flutter.
Torsade de pointes, the most severe adverse
effect associated with amiodarone, has not yet been
reported in humans with dronedarone. Dronedaro-
ne had little effect on thyroid function and hormo-
ne levels in animal models and had no significant
effects on human thyroid function in clinical trials.
Dronedarone could be a useful drug for prevention
of AF and atrial flutter relapses in low-risk patients.
Further experimental studies and long-term
clinical trials are required to provide additional evi-
dence of efficacy and safety [32]. Dronedarone
works by blocking potassium, sodium, and calcium
channels and exhibits antiadrenergic properties.
The drug has been evaluated at doses of 400, 600,
and 800 mg twice daily. It prolonged the time to AF
recurrence to 60–158 days compared with 5–59 days
with placebo and decreased heart rate during AF by
12–25 beats/min in clinical trials. Major adverse
events include gastrointestinal side effects and risk
of proarrhythmia. Dronedarone may increase the
risk of mortality in patients with congestive heart
failure [29].
Dronedarone and amiodarone display similar
antiarrhythmic efficacy post-myocardial infarction,
partly by preventing repolarization inhomogeneity.
However, dronedarone increases bradyarrhythmic
mortality possibly secondary to its negative inotro-
pic effects [33].
Azimilide
Action mechanism. It is an investigational
class III anti-arrhythmic drug that blocks fast (IKr)
and slow (IKs) components of the delayed rectifier
cardiac potassium channels. It is not approved for
use in any country.
Azimilide is a potassium blocker similar to do-
fetilide or sotalol, but it blocks both IKr and IKs.
It does not perform as a beta-blocker like sotalol.
Unlike sotalol, another class III antiarrhythmic
drug, azimilide does not exhibit reverse-use depen-
dence, that is, its binding characteristics and effec-
tiveness are not related to the heart rate. Azimili-
de permits once-daily dosing and limits major fluc-
tuations in blood levels.
Bioavailability. Azimilide is 85% bioavailable,
reaches peak blood concentrations in 6–8 h. Elimi-
nation: with a long exponential half-life of up to
4 days or 114 h. The drug is predominantly hepati-
cally metabolized [34].
Doses. 75 or 125 mg daily.
Clinical use. Azimilide has been developed for
treating both supraventricular and ventricular ta-
chyarrhythmias. Azimilide showed a nonsignificant
trend toward efficacy in maintaining SR in patients
with AF [35]. Azimilide did not demonstrate clini-
cally important or statistically significant efficacy in
reducing the risk for arrhythmia recurrence in pa-
tients with structural heart disease who were in
atrial fibrillation and converted to sinus rhythm [36].
A major randomized prospective placebo-controlled
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trial, AzimiLide post Infarct surVival Evalution
(ALIVE) was reported in the Highlights from the
2001 American Heart Association Scientific Ses-
sions [37].
This trial evaluated the effect of 75 mg and
100 mg of azimilide on all-cause mortality in
3717 recent MI patients (5–21 days post-MI) at risk
for SD. The major focus of the trial was on the
100-mg azimilide dose.
The primary objectives of ALIVE were to de-
termine the effect of 100 mg azimilide on all-cause
mortality in recent MI patients with a left ventri-
cular ejection fraction (LVEF) of 15–35%, and to
evaluate a subgroup at presumed higher risk with
low heart rate variability.
Using the intent to treat analysis, 1690 patients
received placebo and 1691 received 100 mg azimi-
lide. All cause mortality was the same for both gro-
ups. The patient dosing was initiated once daily in
73% of patients in-hospital and 27% out-of-hospi-
tal. Fewer patients in SR at baseline developed
AF/atrial flutter taking 100 mg azimilide (0.5%)
compared with placebo (1.2%, p = 0.04).
The 100-mg and 75-mg azimilide doses have
given a similar safety profile. For those patients who
received 100 mg azimilide, serious adverse events
and serious cardiovascular events occurred in
38.2% and 28.4%, respectively, and were similar
with placebo (37.8% and 30.8%, respectively). The
Event Committee classified five cases of torsade de
pointes in the azimilide group (0.3%) compared with
one patient receiving placebo (0.1%). The cases of
torsade de pointes were associated with one or
more risk factors, including age > 65 years, female
gender, diuretic use, hypokalemia and/or hypoma-
gnesemia or bradycardia.
Patients who received the 100-mg azimilide
dose had severe neutropenia more frequently com-
pared with those given placebo (0.9% vs. 0.2%). All
cases of neutropenia occurred between 25 and 48 days
in the azimilide group. No patients experienced life-
threatening infections, and all patients recovered in
1–18 days, except 1 patient in whom a new myocar-
dial infarction was associated with death.
In summary, azimilide given to high-risk, post-
MI patients who had substantial LV dysfunction
demonstrated no difference in all-cause mortality
compared with placebo, and there appeared to be some
positive effect on prevention of AF/atrial flutter. Azi-
milide did not improve or worsen the mortality of
patients after MI. Low heart rate variability (HRV)
independently identified a subpopulation at high risk
of mortality. Azimilide was safe and effective AF therapy
in patients with depressed LV function after an MI [38].
Food and Drug Administration requires place-
bo controlled efficacy and safety studies as well as
a mortality trial in patients with significant heart di-
sease. Azimilide has completed these trials and
passed these hurdles but almost all of the trials were
outpatient. The FDA’s preference appears to be to
see what would occur in some in-patient trials to
verify under closer monitoring the apparent profi-
les seen so far in the outpatient trials.
Azimilide significantly reduced the recurren-
ce of VT or VF terminated by shocks or antitachy-
cardia pacing in implantable cardioverter defibril-
lator patients, thereby reducing the burden of symp-
tomatic VT [39].
The anti-arrhythmic efficacy of azimilide is sli-
ghtly superior to placebo but significantly inferior
to sotalol in patients with persistent AF. The mo-
dest anti-arrhythmic efficacy and high rate of TdP
and marked QTc prolongation limit azimilide usa-
ge for the treatment of AF [40].
Side effects. The most frequent reported side
effect is headache, with rare serious adverse events
of early reversible neutropenia and TdP. There is
a small increased risk in severe neutropenia, which
occurs relatively early and is reversible. Because
the incidence of neutropenia occurred in such
a small percentage, the FDA would like to see a gre-
ater number of patient exposures to verify that it is
always early and reversible. That would allow them
to develop appropriate insert guidelines.
Studies of azimilide for the treatment of AF
show an overall incidence of TdP of only 0.5% [41].
TdP is the most serious side effect and observed in
patients with other predisposing factors, including
hypokalemia.
Azimilide-associated TdP has characteristics
and risk factors similar to other IKr blockers.
However, there is a distinctive temporal profile.
The TdP events are not concentrated in the first
week. The azimilide associated TdP rate is 1% and
is not increased in patients with low LVEF, even in
women [42].
Interactions. Has no significant drug interac-
tion with digoxin or warfarin. In animal models, co-
administration of ciprofloxacin and azimilide could
cause QT interval prolongation and episodes of
TdP [43].
Ibutilide
Ibutilide is a selective class III antiarrhythmic
agent that when administered intravenously can
terminate AF and atrial flutter. It is an antiarrhyth-
mic medication that helps return the heart to its
normal sinus rhythm.
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Ibutilide reduces abnormal electrical signals
that cause AF by stabilizing the heart muscle tis-
sue. Ibutilide is given intravenously. It acts for only
a short period. The drug is used for the cardiover-
sion of atrial flutter and AF, but it can cause TdP.
Ibutilide is used to quickly convert AF to a SR. It is
used as an alternative to electrical cardioversion or
when electrical cardioversion or sedation is consi-
dered unsafe or inappropriate. Also, it is sometimes
used to make electrical cardioversion more suc-
cessful. The effectiveness of ibutilide depends on
how long you have had AF and whether you have
an underlying heart disease. The longer AF has
been present, the less effective ibutilide is.
Ibutilide is more effective than amiodarone in
converting recent-onset atrial flutter to SR where-
as both drugs are equally effective in converting
recent-onset AF to SR [44].
In children and in patients with congenital he-
art disease with careful monitoring, ibutilide can be
an effective tool in selected patients for cardiover-
sion of atrial flutter [45].
During pregnancy direct current external car-
dioversion is the current method of terminating AF
and atrial flutter. This technique is sometimes con-
sidered undesirable by both physician and patients
due to the need for deep sedation or anesthesia. Ibu-
tilide was used with success to terminate sympto-
matic persistent atrial flutter in a patient during her
24th week of pregnancy [46]. The administration of
amiodarone in the case of ibutilide failure may be
a useful adjunct to current cardioversion protocols
for recent onset AF [47]. Pharmacologic conversion
of AF and atrial flutter has demonstrated conver-
sion rates of 60–80%.
Ibutilide is an excellent therapy option for re-
storing SR in the emergency department. Its use
may obviate the need for admission, the risks and
inconveniences of general anesthesia to perform
electrical cardioversion, and reduce the emergen-
cy department length of stay in selected patients
with recent-onset atrial arrhythmias [48].
Ibutilide can be used for conversion of monomor-
phic atrial tachycardia with a similar efficacy as for AF,
but with a considerably lower efficacy compared to
typical atrial flutter [49]. Although not essential for a
successful outcome, pretreatment with ibutilide can
lower energy requirements in transthoracic biphasic
cardioversion. Cardioversion of AF with monophasic
transthoracic shock is facilitated by pretreatment with
ibutilide [50]. Ibutilide is effective for conversion of
recent onset AF in patients presenting to the emer-
gency department and there is a low rate of compli-
cations from ibutilide in this setting [51].
Intravenous ibutilide is more effective than
intravenous propafenone for the cardioversion of
recent onset AF, and the adverse effects are rare
and transient [52].
Side effects. Ibutilide may cause many side
effects. It should be used carefully, and patients sho-
uld be closely monitored for a minimum of 4 h in
the hospital after receiving ibutilide. Side effects of
ibutilide include:
— fast or slow heartbeat;
— dizziness or lightheadedness;
— headache;
— sudden fainting;
— low blood pressure;
— heart palpitations;
— rapid, uncontrolled heart rhythm: VT, nonsu-
stained monomorphic VT, TdP or VF;
— heart block;
— heart failure;
— nausea;
— shortness of breath;
— swelling of feet or ankles;
— severe allergic reactions (rash, hives, it-
ching, difficulty breathing, tightness in the
chest, swelling of the mouth, face, lips or
tongue).
III. Miscellaneous agents
Trecitilide
Trecitilide is an analog of ibutilide that is oral-
ly effective. Its bioavailability is approx. 70%. It has
a similar mechanism of action to ibutilide.
Tedisamil
Tedisamil is a drug intended for cardiologists
to treat AF and atrial flutter. It is an innovative
drug for now in the later phase of clinical develop-
ment for rapid conversion of AF to normal SR.
It was originally developed as an antianginal agent.
It blocks the delayed rectifier and transient
outward potassium currents. Decreasing heart rate
is potentially useful in ischemic heart disease.
Tedisamil is a bradycardic agent resulting from its
ability to inhibit I(to) in atria. Tedisamil inhibits
I(to), potassium current (IK), K(ATP) and the pro-
tein kinase A-activated chloride channel in ventric-
les as well as vascular IK and Ca2+-activated IK
[IK(Ca)]. Tedisamil prolongs cardiac APs and the
QTc of the ECG and also increases cardiac refrac-
toriness. The bradycardic effect of tedisamil is
associated with a reduction in myocardial oxygen
demand. Diarrhea is a drawback to its further
investigation.
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Ersentilide
Ersentilide (CK-3579) is a novel antiarrhyth-
mic agent which combines blockade of the rapid
component of the delayed rectifier potassium chan-
nel (IKr) with relatively weak beta-adrenergic bloc-
kade. The combination of IKr and weak beta-adre-
nergic blockade, using ersentilide, represents
a very effective and safe antiarrhythmic interven-
tion able to overcome the limitations present in
drugs devoid of any antiadrenergic effect. Such
a combination may be very useful in the manage-
ment of post-myocardial infarction patients at high
arrhythmic risk.
Ambasilide
Ambasilide is a class III antiarrhythmic, has
been shown to block multiple cardiac channels inc-
luding beta-adrenergic antagonism. Although the
electrophysiological effects of ambasilide are cha-
racterized on the cellular level, its effects on an
organ level have yet to be investigated. Ambasilide
prolonged the RR, PQ, QRS, QT, and QTc in a con-
centration-dependent manner in either normal SR
or with reduced heart rate (atriectomy). dP/dtmin was
increased (became less negative) in the presence
of increasing concentrations of ambasilide, where-
as the vehicle produced less negative lusitropy.
Ambasilide demonstrated use dependence by pro-
longing QTc less at slower heart rates [53].
Chromanol 293B
Chromanol 293B is a lead compound of poten-
tial class III antiarrhythmics that inhibit cardiac IKs
potassium channels. It is a relatively selective bloc-
ker of IKs and the frequency dependence of APd
prolongation caused by this IKs blocker is different
from that caused by IKr blockade: 293B may be an
interesting tool to study the physiologic role of IKs
and the antiarrhythmic potential of IKs blockade.
Drugs that selectively inhibit the IKs are being con-
sidered as possible antiarrhythmic agents, becau-
se they produce more prolongation of APd at fast
rates with less transmural dispersion of repolariza-
tion compared with blockers of IKr. IKs are formed
by the coassembly of KCNQ1 (Kv7.1, KvLQT1) and
KCNE1 subunits [54].
Although the chromanol derivative chromanol
293B has been shown to be relatively selective in
blocking IKs in some species, its selectivity is far
from established. Pharmacological IKs block in the
absence of sympathetic stimulation plays little role
in increasing normal human ventricular muscle AP
duration. However, when human ventricular musc-
le repolarization reserve is attenuated, IKs plays an
increasingly important role in limiting AP prolonga-
tion [55].
IKs blockade significantly reduced HF-induced
dispersion of repolarization to values seen in non-
failing hearts. By prolonging repolarization witho-
ut increasing dispersion of repolarization, IKs bloc-
kade may have antiarrhythmic effects without
creating proarrhythmia [56].
Sematilide
A close structural analog of N-acetylprocaina-
mide, prolongs cardiac APs in vitro, whereas it does
not depress maximum AP upstroke slope, a “class
III” action. It is a “pure” class III agent, which acts
largely by delaying conduction. The electrophysio-
logic profile of sematilide is consistent with the se-
lective block of outward potassium currents and as-
sociated isolated lengthening of the ventricular ef-
fective refractory period and AP duration.
Sematilide demonstrates a significant degree
of reverse frequency-dependence of the ventricu-
lar APd and effective refractory period; and suppres-
sion of VT inducibility by sematilide appears to be
correlated with increases in the right ventricular
effective refractory period [57].
Wong et al. [58] report an evaluation of the cli-
nical pharmacologic actions of sematilide in 14 pa-
tients with chronic high-frequency nonsustained
VT. In all, 36 intravenous infusions (range 0.15 to
1.5 mg/kg over 15 min) were administered in
a dose-ranging, placebo-controlled study design.
Sematilide exerts class III actions in patients:
prolongs QTc in a dose- and concentration-related
fashion, does not alter PR or QRS, and slows heart
rate at high concentrations. The relations between
dose and total area under the time-concentration
curve, dose and peak plasma concentration, and
peak plasma concentration and increase in QTc
were linear. QTc increases of approximately equal
to 25% were seen at plasma concentrations of ap-
proximately equal to 2.0 mg/mL. The mean elimi-
nation half-life was 3.6 ± 0.8 h, and most of a dose
(77 ± 13%) was recovered unchanged in the urine.
Plasma concentrations greater than or equal to
0.8 mg/mL suppressed arrhythmias (5 patients) or
aggravated them (3 patients), including 1 patient
who needed cardioversion for an episode of TdP
(2.7  mg/mL) [58].
Treatment of torsade de pointes
in acquired long QT syndrome
Treatment of TdP includes immediate defibril-
lation for hemodynamic instability. The patient with
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TdP who is in extremis should be treated with elec-
trical cardioversion or defibrillation and the drug of
choice: intravenous magnesium sulfate. Magnesium
is usually very effective, even in the patient with
a normal magnesium level. Intravenous MgSO4 in-
fusion effectively treated TdP in children with long
QT syndrome.
Intravenous administration of magnesium sul-
phate (MgSO4) is a very effective and safe treatment
for TdP associated with acquired LQTS in adults.
Alternatives
1. Withdraw causative agents is a very important
conduct. Potassium levels should be maintained
in the high normal range.
2. Isoproterenol: to a rate of 90–100 bpm is effec-
tive.
3. Potassium (if hypokalemic): treat hypokalemia
as if it is the precipitating factor and administer
magnesium sulfate in a dose of 2–4 g intra-
venously initially.
4. A few cases of successful conversion using phe-
nytoin and overdrive pacing have been reported.
5. Cervical sympathectomy and implantable pa-
cemakers/defibrillators have been used in some
cases for long-term management.
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